Sonic Healthcare Limited : There is still some upside potential
Entry price | Target | Stop-loss | Potential |
---|
A$42.35 |
A$45.83 |
A$39.9 |
+8.22% |
---|
The underlying tendency is to the upside for shares in Sonic Healthcare Limited and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Sales forecast by analysts have been recently revised upwards.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
● The average consensus view of analysts covering the stock has deteriorated over the past four months.
● The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.